Hepatitis Therapeutics Market Analysis By Disease Type (Hepatitis A, B, C) By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2014 - 2025

  • ID: 4240446
  • Report
  • Region: Asia, Asia Pacific, Europe, North America, United States
  • 80 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • AbbVie
  • Biocon
  • Bristol-Myers Squibb Co
  • Gilead Lifesciences
  • Johnson & Johnson
  • Merck & Co., Inc.,
  • MORE
The global hepatitis therapeutics market is expected to reach USD 25.8 billion by 2025. The key factors driving market growth include the rising number of infected population, growing consumption of alcohol & drugs, increase in global geriatric population, and improvement in access to hepatitis medicines.

Hepatitis is generally classified into two types based on the duration for which the patient suffers. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic hepatitis.The population at a greater risk of hepatitis include people with HIV infection & HCV-infected sexual partners, who inject drugs & use intranasal drugs, recipients of infected blood products, and other population groups who live in unhygienic conditions.

According to the WHO, globally around 400 million people are infected with at least one form of hepatitis and every year nearly 1.4 people die due to the condition. Various government and private agencies are actively involved in the vaccination drive to prevent hepatitis. Hepatitis C leads to more serious complications compared to hepatitis A and B. As per WHO estimates, nearly 150 million are impacted by hepatitis C infection globally. Moreover, a significant number of hepatitis C patients develop liver cancer or liver cirrhosis and nearly 700,000 people die due to hepatitis C infection & associated conditions.

Further Key Findings From the Report Suggest:

Due to very high prevalence of target disease coupled with subsequent increase in the treatment rate Hepatitis C accounted for the majority market share of 75.6% in 2016

In 2016, North America held the largest share of nearly 42.9%. The key factors attributed to the regions high share include high patient awareness levels and the presence of advanced healthcare infrastructure.

Asia Pacific is anticipated to witness the maximum growth with a CAGR of 5.8% over the forecast period. High economic development coupled with rapidly increasing healthcare expenditure are amongst key factors attributing to the regions high growth rate.

Key players include Gilead, Merck & Co. Inc., Johnson & Johnson, Bristol-Myers Squibb Company, and AbbVie Inc.
PLEASE NOTE: This report will be completed after order and will take approximately 1-2 business days after the confirmation of payment.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Biocon
  • Bristol-Myers Squibb Co
  • Gilead Lifesciences
  • Johnson & Johnson
  • Merck & Co., Inc.,
  • MORE
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
2. Executive Summary
2.1. Market Snapshot
3. Hepatitis Therapeutics Market Variables, Trends& Scope
3.1. Market Segmentation
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Key Opportunities Prioritized
3.4. Industry Analysis - Porter's
3.5. Hepatitis Therapeutics Market-SWOT Analysis, By Factor (political & legal, economic and technological), 2015
4. Hepatitis Therapeutics Market: Disease Type Estimates & Trend Analysis
4.1. Hepatitis Therapeutics Market Share by Disease Type, 2015 & 2025 (USD Million)
4.2. Hepatitis A
4.2.1. Market estimates and forecast, 2014 - 2025 (USD Million)
4.3. Hepatitis B
4.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
4.4. Hepatitis C
4.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
4.5. Others
4.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5. Hepatitis Therapeutics Market: Regional Outlook
5.1. Hepatitis Therapeutics Market share by region, 2015 & 2025 (USD Million)
5.2. North America
5.2.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.2.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.2.3. U.S.
5.2.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.2.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.2.4. Canada
5.2.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.2.4.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.3. Europe
5.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.3.3. Germany
5.3.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.3.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.3.4. UK
5.3.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.3.4.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.4. Asia Pacific
5.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.4.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.4.3. China
5.4.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.4.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.4.4. Japan
5.4.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.4.4.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.5. Latin America
5.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.5.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.5.3. Brazil
5.5.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.5.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.5.4. Mexico
5.5.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.5.4.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.6. Middle East & Africa
5.6.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.6.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.6.3. South Africa
5.6.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.6.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
6. Competitive Landscape
6.1. Strategic Framework
6.2. Gilead Lifesciences
6.2.1. Company overview
6.2.2. Financial performance
6.2.3. Product benchmarking
6.2.4. Strategic initiatives
6.3. Bristol-Myers Squibb Co
6.3.1. Company overview
6.3.2. Financial performance
6.3.3. Product benchmarking
6.3.4. Strategic initiatives
6.4. Biocon
6.4.1. Company overview
6.4.2. Financial performance
6.4.3. Product benchmarking
6.4.4. Strategic initiatives
6.5. AbbVie
6.5.1. Company overview
6.5.2. Financial performance
6.5.3. Product benchmarking
6.5.4. Strategic initiatives
6.6. Merck & Co., Inc.,
6.6.1. Company overview
6.6.2. Financial performance
6.6.3. Product benchmarking
6.6.4. Strategic initiatives
6.7. Johnson & Johnson
6.7.1. Company overview
6.7.2. Financial performance
6.7.3. Product benchmarking
6.7.4. Strategic initiatives

List of Tables

Table 1 hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 2 North America hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 3 U.S. hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 4 Canada hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 5 Europe hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 6 Germany hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 7 UK hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 8 Asia Pacific hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 9 China hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 10 Japan hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 11 Latin America hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 12 Brazil hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 13 Mexico hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 14 Middle East & Africa hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 15 South Africa hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)

List of Figures

Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Primary research pattern
Figure 4 Market summary
Figure 5 Market trends & outlook
Figure 6 Market segmentation & scope
Figure 7 Market driver relevance analysis (Current & future impact)
Figure 8 Market restraint relevance analysis (Current & future impact)
Figure 9 Key Opportunity Priorities
Figure 10 SWOT Analysis, By Factor (political & legal, economic and technological)
Figure 11 Porter’s Five Forces Analysis
Figure 12 Hepatitis therapeutics market, Heat Map Analysis
Figure 13 Hepatitis therapeutics market product outlook key takeaways
Figure 14 Hepatitis therapeutics market: Disease type movement analysis
Figure 15 Hepatitis A market, 2014 - 2025 (USD Million)
Figure 16 Hepatitis B market, 2014 - 2025 (USD Million)
Figure 17 Hepatitis C market, 2014 - 2025 (USD Million)
Figure 18 Other hepatitis therapeutics market, 2014 - 2025 (USD Million)
Figure 19 Regional outlook, 2015 & 2024
Figure 20 North America hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 21 U.S. hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 22 Canada hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 23 Europe hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 24 Germany hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 25 UK hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 26 Asia Pacific hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 27 China hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 28 Japan hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 29 Latin America hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 30 Brazil hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 31 Mexico hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 32 MEA hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
Figure 33 South Africa hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Gilead Lifesciences
  • Bristol-Myers Squibb Co
  • Biocon
  • AbbVie
  • Merck & Co., Inc.,
  • Johnson & Johnson
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll